The safety of agomelatine in standard medical practice in depressed patients: A 26‐week international multicentre cohort study - Archive ouverte HAL Access content directly
Journal Articles Human Psychopharmacology: Clinical and Experimental Year : 2020

The safety of agomelatine in standard medical practice in depressed patients: A 26‐week international multicentre cohort study

(1) , (2) , (3, 4) , (5) , (6) , (7) , (8) , (9) , (10) , (10) , (10) , (10)
1
2
3
4
5
6
7
8
9
10

Abstract

Objective: The present observational cohort study documented the safety of agomelatine in current medical practice in out-patients suffering from major depressive disorder. Method: The 6-month evolution of agomelatine-treated patients was assessed with a focus on safety (emergent adverse events, liver acceptability), severity of depression using the Clinical Global Impression Severity (CGI-S) score, and functioning measured by the Sheehan Disability Scale (SDS). Results: A total of 8453 depressed patients from 761 centres in 6 countries were analysed (female: 67.7%; mean age: 49.1 ± 14.8 years). Adverse events reported were in accordance with the known safety profile of agomelatine. Cutaneous events were reported in 1.7% of the patients and increased hepatic transaminases values were reported in 0.9 % of the patients. The incidence of events related to suicide/self-injury was 1.0%. Two completed suicides, not related to the study drug, were reported. CGI-S total scores and SDS sub-scores improved and numbers of days lost or underproductive decreased over the treatment period. Conclusions: In standard medical practice, agomelatine treatment was associated with a low incidence of side effects. No unexpected events were reported. A decrease in the severity of the depressive episode and improved functioning were observed. Trial registration name: Observational cohort study to evaluate the safety of agomelatine in standard medical practice in depressed patients. A prospective, observational (non-interventional), international, multicentre cohort study. Trial registration number: ISRCTN53570733.
Fichier principal
Vignette du fichier
Gorwood et al 2020 Hum Psychopharmacol.pdf (330.51 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-02969124 , version 1 (16-10-2020)

Identifiers

Cite

Philip Gorwood, Jacques Benichou, Nicholas Moore, Enric Álvarez Martínez, Joost Mertens, et al.. The safety of agomelatine in standard medical practice in depressed patients: A 26‐week international multicentre cohort study. Human Psychopharmacology: Clinical and Experimental, 2020, pp.e2759. ⟨10.1002/hup.2759⟩. ⟨inserm-02969124⟩
44 View
50 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More